EOI::implementing the presidents department of government efficiency cost efficiency initiative (march 19, 2025)::EOI full termination
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93023C00033
- Awardee
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $599,925
Award facts
- Opportunity
-
- PHS202301 Solicitation number
- Contract value 17% obligated
-
- $599,925.00 Current, with exercised options
- $3,599,784.00 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 10 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- CRYSTAL CITY, CA 90220, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Original award | $599,925 |
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a $3,599,784.00 Firm Fixed Price contract to Molecular Express, Inc., a minority-owned, self-certified small disadvantaged business, for the DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151. This definitive contract does not have a set-aside designation and is scheduled for completion by September 29, 2028. Molecular Express, Inc. specializes in developing innovative drug formulations, therapeutics, and vaccine technologies, particularly focused on infectious diseases and respiratory health solutions. This contract supports the company's continued work with NIAID on advancing medical research through specialized technological platforms, including projects related to HIV vaccine research and developing treatments for respiratory conditions.
Quick answers
Who was awarded contract 75N93023C00033?
75N93023C00033 was awarded to Molecular Express, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 30, 2023.
How much is contract 75N93023C00033 worth?
The government has obligated $599,925 on 75N93023C00033. Its potential value, with all options, is $3,599,784.
Was contract 75N93023C00033 competed?
The extent of competition for 75N93023C00033 was full and open competition. The government received 10 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award